These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28631120)

  • 1. [Erratum to: Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk. Comparative analysis with leuprolide on the basis of the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):924. PubMed ID: 28631120
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice.
    Knutsson A; Hsiung S; Celik S; Rattik S; Mattisson IY; Wigren M; Scher HI; Nilsson J; Hultgårdh-Nilsson A
    Sci Rep; 2016 May; 6():26220. PubMed ID: 27189011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs.
    Pappa EV; Zompra AA; Spyranti Z; Diamantopoulou Z; Pairas G; Lamari FN; Katsoris P; Spyroulias GA; Cordopatis P
    Biopolymers; 2011; 96(3):260-72. PubMed ID: 20632397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane.
    Sánchez CA; Mercado AJ; Contreras HR; Cabezas JC; Huidobro CC; Castellón EA
    Anticancer Drugs; 2012 Oct; 23(9):959-69. PubMed ID: 22713594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
    Sánchez C; Clementi M; Benitez D; Contreras H; Huidobro C; Castellón E
    Prostate; 2005 Nov; 65(3):195-202. PubMed ID: 15948150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
    Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
    Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
    Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
    BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model.
    Taniguchi H; Katano T; Nishida K; Kinoshita H; Matsuda T; Ito S
    Andrology; 2016 Sep; 4(5):964-71. PubMed ID: 27230983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
    Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.
    Ko YH; Ha YR; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Cheon J
    J Int Med Res; 2011; 39(3):729-39. PubMed ID: 21819703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.
    Salciccia S; Gentilucci A; Cattarino S; Sciarra A
    Urologia; 2016 Nov; 83(4):173-178. PubMed ID: 27768220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
    Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
    World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.